Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20078856 | 0.88 | FDPS (0.43) | FDPSALDH1A1MAPTMAOBDPP4 | |
| SCHEMBL12723733 | 0.87 | TTR (0.42) | ALDH1A1MAPTDPP4TTRPKM | |
| SCHEMBL1590146 | 0.85 | ALDH1A1 (0.41) | ALDH1A1MAPTGLAPKMHPGD | |
| SCHEMBL1590147 | 0.85 | ALDH1A1 (0.41) | ALDH1A1MAPTGLAPKMHPGD | |
| SCHEMBL1589937 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPTGLAPKMHPGD | |
| SCHEMBL13556356 | 0.72 | RAB9A (0.45) | ALDH1A1MAPTGLAHPGDKDM4E | |
| SCHEMBL1589648 | 0.72 | ADORA2A (0.47) | ALDH1A1PKMHPGDKDM4ELMNA | |
| SCHEMBL18905207 | 0.70 | ALDH1A1 (0.54) | ALDH1A1MAPTHPGDKDM4ELMNA | |
| SCHEMBL15243719 | 0.69 | KCNA6 (0.51) | ALDH1A1MAPTDPP4TTRPKM | |
| SCHEMBL16342351 | 0.68 | CA1 (0.50) | FDPSALDH1A1MAPTMAOBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947073-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2019-04-03 | — | — | EP | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| EP-2947073-A2 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics Pty Ltd (AU) | 2015-11-25 | — | — | EP | disclosed |
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-09-24 | — | — | US | disclosed |
| EP-2491030-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-07-15 | — | — | EP | disclosed |
| US-9062076-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | FDPS 558/4885ALDH1A1 1066/4885MAPT 4668/4885 |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | FDPS 558/4885ALDH1A1 1066/4885MAPT 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.